MediMabBio
Seongnam
About MediMabBio
MediMabBio platform uses systems biology combined with sophisticated immunological solutions to identify significantly improving immuno-oncology drugs that can actively target a range of solid tumors. The antibody discovery I-O platform brings the advantages of rational drug design to large molecule therapeutic development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $17.8M
- Funding stage: Early Stage Venture
- Last round: Series B (Oct 2025)
- Website: medimabbio.com
- Phone: +82 31-623-2100
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/medimabbio-49175 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.